The New York Times
Monday, August 01, 2016
Archeological Finds Push First Known Cancer Back 2 Million Years (not new eg. breast cancer Egyptian times)
medical news
FRIDAY, July 29, 2016 (HealthDay News) -- Researchers report that they have unearthed the earliest evidence of bone tumors and cancers, dating back almost 2 million years.
The discoveries challenge the belief that cancer is a disease of modern life, the study authors said.
"Modern medicine tends to assume that cancers and tumors in humans are diseases caused by modern lifestyles and environments. Our studies show the origins of these diseases occurred in our ancient relatives millions of years before modern industrial societies existed,"....
Alcohol Use & Breast Cancer Survival (WHI) - spoiler alert - No
Abstract
Conclusion: In this large study, consumption of alcohol before or after breast cancer diagnosis did not increase risks of overall or
cause-specific mortality.
Impact: Coupled with existing evidence, alcohol consumption is unlikely to have a substantial impact on mortality among breast cancer
patients. Cancer Epidemiol Biomarkers Prev; 25(8); 1268–73. ©2016 AACR.
Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in BRCA1/2 Mutation Carriers
abstract
Conclusion: A parent-of-origin effect is present after correction for referral bias by family history, but correction for the personal
cancer history made the effect disappear.
Impact: There is no conclusive evidence regarding incorporating a BRCA1/2 parent-of-origin effect in breast cancer risk prediction models. Cancer Epidemiol Biomarkers Prev; 25(8); 1251–8. ©2016 AACR.
open access: Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers
open access:
Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review
Purpose: To systematically investigate the effectiveness of prophylactic surgeries (PS) implemented in women carrying BRCA1/2 mutations.
Sunday, July 31, 2016
MSH3 Gene - GeneCards (endometrial, bladder, gastric, clear cell ovarian...)
MSH3 Gene
Disorder
| Aliases | PubMed IDs | |
|---|---|---|
| endometrial cancer 16 2346 91 142 |
| |
| superficial urinary bladder cancer 91 |
| |
| gastric leiomyoma 91 |
| |
| phlebotomus fever 91 |
| |
| ovarian clear cell carcinoma 191 |
|
Microsatellite status and immunohistochemical features of ovarian clear-cell carcinoma.
Ovarian clear-cell carcinoma (OCC) is known to have a poor prognosis and selected genetic features of OCC
remain unknown. We investigated microsatellite instability (MSI) and
the expression of the DNA mismatch repair-related protein, p53. MSI was
examined by polymerase chain reaction using mono-, di-, tri- and
tetranucleotide repeat markers, and hMSH2, hMLH1, hMSH6, MSH3 and p53 were determined immunohistochemically in 24 cases of OCC.
A total of 9 (37.5%) cases exhibited MSI. Two cases (8.3%) exhibited
MSI-H in mononucleotide repeat loci with the negative expression of
hMLH1, while another 7 cases (29.2%) exhibited selected trinucloetide
repeat MSI (MSI-TR). Of these MSI-TR cases, 4 cases (57.1%) were
determined to be negative for MSH3, while hMSH2, hMSH6, MSH3 and p53 expressions were normal. Our findings suggest that MSI-TR would be a feature indicating the microsatellite status in OCC, and that the loss of MSH3 expression may promote MSI-TR.
open access: Menopausal hormone therapy and breast cancer: what is the true size of the increased risk? (UK study)
British Journal of Cancer
The BGS is a cohort study of 113 693 women from the United Kingdom, aged16 years, from whom questionnaire information and informed consent was gained at recruitment during 2003–2015. The first follow-up questionnaire was completed at 2.5 years after recruitment, a second at ~6 years, and a third at 9.5 years. The study was approved by the South East Multi-Centre Research Ethics Committee.
Conclusions:
Lack of updating MHT status through follow-up and inclusion of women with inferred menopausal age is likely to result in substantial underestimation of the excess relative risks for oestrogen plus progestogen MHT use in studies with long follow-up, limited updating of exposures, and changing or short durations of use.Ovarian and tubal cancer in Denmark: An update on incidence and survival
abstract
Introduction
The Nordic countries are high-incidence areas of ovarian cancer, however, differences between the countries exist.
Material and Methods
We
used the Danish Cancer Registry to identify 11 264 cases of ovarian
cancer and 363 cases of tubal cancer during 1993–2013. We calculated
age-standardized (WSTP) incidence rates for overall and subtype-specific
ovarian cancer, and for tubal cancer. We compared age-standardized
incidence rates, and 1- and 5-year age-standardized relative survival
rates, respectively, for ovarian and tubal cancer combined in four
Nordic countries using the NORDCAN database.
Results
The
incidence rate of ovarian cancer overall in Denmark decreased
statistically significant by approximately 2.3% per year among women
aged <70 years, whereas no change was seen among women aged 70+
years. In the <70 age-group, the incidence of serous tumors was
fairly steady, whereas that of other and unspecified epithelial tumors
decreased significantly by 6.4% per year. The incidence of tubal cancer
was quite stable. In Norway and Finland, the incidence rates of ovarian
and tubal cancer combined decreased from 1993 to 2013 in women aged
<70 years, whereas in Sweden the incidence rates decreased
independently of age. The 1- and 5-year relative survival rates of
ovarian and tubal cancer combined increased during the study period in
all the Nordic countries. Denmark had the lowest survival, however, the
survival rates approached those of the other countries in recent years.
Conclusions
In
Denmark, the positive development in ovarian cancer has continued
during recent years with a lower incidence and an increased survival.
Mammography in women with an implanted medical device: impact on image quality, pain and anxiety
abstract
Advances in knowledge:
Subscribe to:
Posts
(
Atom
)
